Peter Borchmann

TH Köln - University of Applied Sciences

Also affiliated with University of Cologne, Düsseldorf University Hospital, Integrated Oncology (United States), German Inflammatory Bowel Diseases Study Group, Nordic Lymphoma Group, Lungenklinik Köln-Merheim, Centrum für Integrierte Onkologie, University Hospital Cologne, Heinrich Heine University Düsseldorf

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 6 papers. Top paper: “Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR”.

Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR

European Journal of Haematology(2024)10.1111/ejh.14191

N/A

0.411DataRank · unranked

8 citations

Yannick d'Hargues, Fanni Kleinert, Julia Mattlener, Jonathan Weiss, Fabian Franzen +14 more

Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial

Journal of Clinical Oncology(2025)10.1200/jco-25-00439

N/A

0.406DataRank · unranked

14 citations

Helen Kaul, Alexander Fosså, Andreas Hüttmann, Felix Keil, Yon-Dschun Ko +30 more

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

Blood Advances(2024)10.1182/bloodadvances.2023012145

N/A

0.391DataRank · unranked

9 citations

Fer de Wit, Alex F. Herrera, Pier Luigi Zinzani, Ann S. LaCasce, Peter D. Cole +12 more

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study

The Lancet Oncology(2025)10.1016/s1470-2045(24)00598-9

N/A

0.373DataRank · unranked

11 citations

Emily Mitchell, My H Pham, Rashesh Sanghvi, Janina Jablonski, Henry Lee-Six +51 more

CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL

Hematological Oncology(2023)10.1002/hon.3163_15

N/A

0DataRank · unranked

6 citations

Andrés J.M. Ferreri, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer +45 more

142 | LISOCABTAGENE MARALEUCEL IN R/R FL (TRANSCEND FL): IMPACT OF PRIOR LINES OF THERAPY, BENDAMUSTINE EXPOSURE, AND DISEASE PROGRESSION ≤ 24 MONTHS OF INITIAL SYSTEMIC THERAPY

Hematological Oncology(2025)10.1002/hon.70093_142

N/A

0DataRank · unranked

0 citations

Juan Luis Reguera Ortega, Franck Morschhauser, Guillaume Cartron, Aaron P. Rapoport, Koji Izutsu +14 more